Kintor Pharmaceutical Limited



简体

繁体

搜索

PREV 

NEXT 

About Us

Kintor Pharmaceuticals focuses on developing drugs for androgen-receptor-related diseases with significant unmet medical needs，

including prostate cancer, breast cancer, liver cancer, COVID-19, alopecia, acne, and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Small-molecule drugs

Kintor Pharmaceuticals product pipeline initially focused on androgen receptor (AR) antagonists. Our expanded pipeline now includes mTOR inhibitors, Hedgehog inhibitors, AR protein degradation agents, and cMyc inhibitors.

Innovative biologics

Kintor Pharmaceuticals' first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers.

Combination therapies

To provide the best treatment for prostate, breast, and liver cancers and other diseases, Kintor Pharmaceuticals is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a multidisciplinary team of drug developers.

Manufacturing Base

Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing base in Suzhou.

Commercial Operation

In anticipation of the commercial launch of our products, Kintor Pharmaceuticals is building an independent commercialization team. [entity?]

R&D Platform

We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.

Manufacturing Base

A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.

Commercial Operation

In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.

News Center

2022-12-01

Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met

Suzhou, December 1, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced results of phase II clinical trial of pyrilutamide (KX-826), a potential first-in-class topical drug developed by the company, in China for the treatment of adult female androgenetic alopecia (AGA). In the study, KX-826 has demonstrated clinically meaningful and statistically significant improvement in hair growth as measured by target area non-vellus hair count (TAHC). In addition, its safety profile was favorable.

2022-11-24

Kintor Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use

Suzhou, November 24, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the top-line results for its phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne in China, which demonstrated the good safety, tolerability and pharmacokinetics of GT20029 in healthy subjects. Developed by Kintor Pharma’s proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the first topical PROTAC compound globally which has completed phase I clinical trial.

2022-11-10

Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715

Suzhou, November 10, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the results from the novel dual c-Myc/GSPT1 degrader GT19715 have been selected for oral presentation at the annual meeting of the American Society of Hematology 2022 (ASH 2022), and the abstract is available on ASH’s official website.